Wells Fargo’s Unicycive Therapeutics UNCY Stock Holding History
Bought
Maintained
Sold
Other funds holding UNCY
Wells Fargo's UNCY Position: Q3 2026 in Review
Wells Fargo reduced its Unicycive Therapeutics (UNCY) stake by 68% in Q3 2026, selling an estimated $77.6K and leaving 7,103 shares worth $33.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5709.
Wells Fargo first reported a position in UNCY in Q3 2021 and has held it in 13 quarters since. The position peaked at $104K in Q2 2026. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.
- Wells Fargo held 7,103 shares of Unicycive Therapeutics worth $33.3K as of Q3 2026.
- Wells Fargo sold 14,966 Unicycive Therapeutics shares in Q3 2026, an estimated $77.6K.
- Unicycive Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5709 holding.
- Wells Fargo first reported a position in Unicycive Therapeutics in Q3 2021 and has held it in 13 quarters since.
- Wells Fargo's Unicycive Therapeutics position peaked at $104K in Q2 2026.
- 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.